Online inquiry

IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11078MR)

This product GTTS-WQ11078MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CSF1 gene. The antibody can be applied in Pigmented villonodular synovitis (PVNS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000757.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1435
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11078MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ902MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ12776MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ554MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ2875MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ12470MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ4635MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ6731MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
GTTS-WQ6245MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR57
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW